Ruconest is estimated to cost $12,905 per attack.
Understanding Ruconest's Cost
Ruconest is an on-demand treatment used for acute attacks of Hereditary Angioedema (HAE). Its cost is typically evaluated per attack, reflecting the nature of its usage as a treatment administered during an acute episode.
Ruconest's Cost-Effectiveness
In analyses comparing various on-demand treatments for HAE attacks, Ruconest has been identified as a highly cost-effective option. Among four commonly analyzed treatments, it was estimated to be the most cost-effective.
Here's a comparison of estimated costs per attack for several on-demand HAE treatments:
| Treatment | Estimated Cost Per Attack |
|---|---|
| Ruconest | $12,905 |
| Berinert | $14,668 |
| Firazyr | $14,806 |
| Kalbitor | $21,068 |
As seen in the table, Ruconest's estimated cost per attack is notably lower than that of other widely used treatments for HAE. This makes it a significant consideration for patients and healthcare providers managing HAE.
Factors Influencing Medication Costs
It's important to note that the actual out-of-pocket cost for patients can vary based on several factors:
- Insurance Coverage: Most patients rely on health insurance, and coverage details (co-pays, deductibles, formularies) will significantly impact the final cost.
- Patient Assistance Programs: Manufacturers often offer programs to help eligible patients afford their medications.
- Pharmacy Discounts: Some pharmacies or discount cards might offer lower prices.
- Geographic Location: Medication prices can differ by region or country.
- Dosage and Frequency: While the cost is per attack, the overall annual cost depends on the frequency of HAE attacks and the amount of medication required for each.
These estimated costs represent the direct cost of the medication per attack, often used in economic evaluations of treatments. Patients should consult with their healthcare provider and insurance company to understand their specific financial responsibilities.
